Add like
Add dislike
Add to saved papers

Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry.

Data from the NAPRTCS database were analyzed for growth, allograft function, and targeted adverse events (AE) over a 5-year period in 513 recipients who received recombinant human growth hormone (rhGH) treatment and compared with the outcome of 2,263 concurrent controls who did not receive rhGH. Recipients less than 10 years of age grew better than older recipients. Final adult height was superior in the rhGH-treated group compared with the control group. Allograft function and graft failure rate was similar in the rhGH-treated and control groups. No increased incidence of AE was noted in the rhGH-treated group. rhGH is effective and safe for use in growth-retarded pediatric renal allograft recipients.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app